Micro-Sphere to boost its spray drying capabilities
CDMO to invest over €3 million in GMP facility expansion.
Spray drying specialist and capsule filling service provider Micro-Sphere is investing 3.5 million CHF (€3.2 million) into expanding its GMP manufacturing capabilities and processes.
Micro-Sphere will add an additional spray drying line to its facility in Switzerland in response to increased market demand for spray drying and capsule filling for dry powder inhalers.
The new production line, expected to be operational by Q1 2021, is Micro-Sphere’s fifth and will allow the CDMO to handle larger quantities of pharmaceutical powders and commercial volumes of finished dosage forms.
Commenting on the investment, Michael Grassberger, Managing Director at Micro-Sphere said: “Our decision to invest has been fuelled by greater demand for spray drying services and we expect it will generate significant benefits for our clients. Our flexibility is key to our success and this investment allows us to maintain that competitive advantage.”
The Swiss facility, already home to some of the world’s leading spray drying and capsule filling technologies, will also benefit from the introduction of a new enterprise resource planning (ERP) system and ‘Chromeleon’ a Chromatografy Data System (CDS) software to support the QC Lab workflow.
Both software systems will bring significant cost and time savings to the business and streamline process efficiency.
Michael Grassberger added: “This year we have focused on making the necessary investments to prepare Micro-Sphere for growth in 2019 and beyond. As well as investing in new machinery to increase our capabilities and expertise, we have also made significant investment into the latest technology. This includes investing in software platforms to ensure the most efficient and robust quality and documentation management systems are in place.
“At Micro-Sphere we’re committed to client satisfaction and ensuring our customers continue to receive the efficient and flexible service that they’re used to, so we’re always looking for ways to further improve our operations to allow us to better cater for their projects.
“This investment further demonstrates our commitment to meeting and exceeding the expectations of our customers and our experienced team are very excited to bring these investments into operation.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.